Larson Financial Group
AQST icon

Larson Financial Group’s Aquestive Therapeutics AQST Stock Holding History

Larson Financial Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13K Sell
2,803
-726
-21% -$3.23K ﹤0.01% 2377
2026
Q2 		$14.7K Sell
3,529
-21
-0.6% -$88 ﹤0.01% 2186
2026
Q1 		$14.7K Buy
+3,550
New +$14.4K ﹤0.01% 2016

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Larson Financial Group's AQST Position: Q3 2026 in Review

Larson Financial Group reduced its Aquestive Therapeutics (AQST) stake by 21% in Q3 2026, selling an estimated $3.23K and leaving 2,803 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

Larson Financial Group first reported a position in AQST in Q1 2026 and has held it in 3 quarters since. The position peaked at $14.7K in Q1 2026. 68 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Larson Financial Group held 2,803 shares of Aquestive Therapeutics worth $13K as of Q3 2026.
  • Larson Financial Group sold 726 Aquestive Therapeutics shares in Q3 2026, an estimated $3.23K.
  • Aquestive Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2377 holding.
  • Larson Financial Group first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Larson Financial Group's Aquestive Therapeutics position peaked at $14.7K in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.